Hormone Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Hormone Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-09-10Clinical Trial Update: Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer [Phase 2]
Phase 2 trial comparing neoadjuvant letrozole plus metformin versus letrozole plus placebo in ER-positive postmenopausal breast cancer compl…
-
CLINICAL_TRIALS research · 2018-04-09Clinical Trial Update: Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers [Phase 3]
Phase 3 trial update evaluating whether using circulating tumor cells to guide first-line treatment for metastatic, hormone-receptor-positiv…
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab [Phase 4]
Phase 4 trial update describes patient preferences for combining everolimus with exemestane or capecitabine with bevacizumab in recurrent HE…
-
CLINICAL_TRIALS research · 2017-07-02Clinical Trial Update: Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer [Phase 2]
This Phase 2 clinical trial compares capecitabine versus endocrine therapy as a maintenance regimen after second-line treatment in hormone r…
-
CLINICAL_TRIALS trial_result · 2017-04-11Clinical Trial Update: Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer [Phase 2]
Phase 2 trial update for an investigational vaccine therapy in stage IV hormone receptor-positive breast cancer has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2016-06-15Clinical Trial Update: Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer [Phase 3]
This document provides an update on a Phase 3 clinical trial evaluating a combination of fulvestrant, everolimus, and exemestane for metasta…
-
CLINICAL_TRIALS trial_result · 2016-05-11Clinical Trial Update: Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic [Phase 2]
A randomized Phase II trial assessed letrozole with or without dasatinib in postmenopausal women with hormone receptor-positive, HER2-negati…
-
CLINICAL_TRIALS trial_result · 2016-01-11Clinical Trial Update: LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer
This ClinicalTrials.gov entry NCT01561443 reports on treatment patterns for postmenopausal women with hormone receptor-positive breast cance…